Other Information.
−Removed: (c) During the three months ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: (c) During the three months ended June 30, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q.
3 unchanged sentences
Exhibit Description
−Removed: Omnibus Agreement, dated as of October 28, 2025 and amended on February 26, 2026, by and between Eloxx Pharmaceuticals, Inc.
−Removed: and the Cystic Fibrosis Foundation.
−Removed: March 17, 2026
−Removed: Royalty and Revenue Sharing Agreement, dated as of July 10, 2024 and amended by Amendment No.1 dated March 2, 2026, by and between the Company, SD MF 4 LLC and the other parties thereto.
−Removed: March 17, 2026
−Removed: Amendment No.
−Removed: 3 Securities Purchase Agreement, dated as of February 20, 2026 by and among the Company, Coastlands Capital, LP and SD MF 4 LLC.
−Removed: March 17, 2026
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Eloxx Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on May 29, 2026
Form of Amended and Restated Pre-Funded Warrant, pursuant to the Securities Purchase Agreement dated as of April 27, 2026
+Added: Form of Pre-Funded Warrant issued pursuant to the Underwriting Agreement, dated as of June 4, 2026
+Added: Form of Pre-Funded Warrant issued pursuant to the Underwriting Agreement, dated as of June 8, 2026
+Added: Amendment No.1 to the Registration Rights Agreement, dated as of June 1, 2026.
+Added: Eloxx Pharmaceuticals, Inc.
+Added: 2018 Amended and Restated Equity Incentive Plan.
Certification of the Company’s Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
22 unchanged sentences
ELOXX PHARMACEUTICALS, INC.
+Added: August 11, 2026
/s/ Daniel E.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.